{"disease":{"id":"glioblastoma-multiforme","name":"Glioblastoma multiforme","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":16},"drugs":{"marketed":[{"drug_id":"bevacizumab","indication_name":"Glioblastoma multiforme","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avastin","generic_name":"bevacizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":82,"revenue":"2100","mechanism":"Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors."},{"drug_id":"carmustine","indication_name":"Glioblastoma multiforme of brain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gliadel","generic_name":"CARMUSTINE","company_name":"Avet Lifesciences","drug_phase":"marketed","molecular_target":"Glutathione reductase, mitochondrial","drug_class":"Alkylating Drug","quality_score":10,"revenue":null,"mechanism":"Gliadel works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and grow."},{"drug_id":"zirabev","indication_name":"Glioblastoma multiforme","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bevacizumab","generic_name":"Bevacizumab-Bvzr","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular Endothelial Growth Factor (VEGF)","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Bevacizumab binds VEGF and prevents interaction with endothelial cell receptors Flt-1 and KDR."},{"drug_id":"avastin","indication_name":"Glioblastoma multiforme","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avastin","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"carmustin","indication_name":"Glioblastoma multiforme of brain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Carmustin","company_name":"University Hospital Freiburg","drug_phase":"marketed","molecular_target":"Glutathione reductase, mitochondrial","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"temozolomide","indication_name":"Glioblastoma multiforme of brain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Temodar","generic_name":"temozolomide","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Alkylating Drug [EPC]","quality_score":10,"revenue":null,"mechanism":"Temodar works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death."},{"drug_id":"temodal","indication_name":"Glioblastoma multiforme of brain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Temodal","company_name":"Armando Santoro, MD","drug_phase":"phase_1","molecular_target":"","drug_class":"","quality_score":3,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":7,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06146738","title":"The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)","phase":"","overall_status":"RECRUITING","enrollment_count":1015,"lead_sponsor_name":"Jasper Gerritsen","has_results":false},{"nct_id":"NCT03896958","title":"The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"SpeciCare","has_results":false},{"nct_id":"NCT04471844","title":"Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM","phase":"NA","overall_status":"COMPLETED","enrollment_count":981,"lead_sponsor_name":"NovoCure Ltd.","has_results":false},{"nct_id":"NCT06118723","title":"The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)","phase":"","overall_status":"RECRUITING","enrollment_count":784,"lead_sponsor_name":"Jasper Gerritsen","has_results":false},{"nct_id":"NCT03722355","title":"Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":712,"lead_sponsor_name":"Radiation Therapy Oncology Group","has_results":false},{"nct_id":"NCT00031538","title":"Genetic Analysis of Brain Tumors","phase":"","overall_status":"TERMINATED","enrollment_count":674,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06146725","title":"The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)","phase":"","overall_status":"RECRUITING","enrollment_count":564,"lead_sponsor_name":"Jasper Gerritsen","has_results":false},{"nct_id":"NCT01631552","title":"Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":515,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT05624736","title":"Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","has_results":false},{"nct_id":"NCT03175224","title":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":497,"lead_sponsor_name":"Apollomics Inc.","has_results":false},{"nct_id":"NCT06283927","title":"The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)","phase":"","overall_status":"RECRUITING","enrollment_count":464,"lead_sponsor_name":"Jasper Gerritsen","has_results":false},{"nct_id":"NCT05271240","title":"Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":432,"lead_sponsor_name":"Northwell Health","has_results":false},{"nct_id":"NCT02414165","title":"The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":403,"lead_sponsor_name":"Tocagen Inc.","has_results":false},{"nct_id":"NCT06348693","title":"Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","has_results":false},{"nct_id":"NCT05839379","title":"Targeted Pediatric High-Grade Glioma Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"Nationwide Children's Hospital","has_results":false},{"nct_id":"NCT05934630","title":"Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors","phase":"","overall_status":"SUSPENDED","enrollment_count":300,"lead_sponsor_name":"Pediatric Brain Tumor Consortium","has_results":false},{"nct_id":"NCT04762069","title":"A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":252,"lead_sponsor_name":"CNS Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT03861299","title":"The SAFE-Trial: Awake Craniotomy Versus Surgery Under General Anesthesia for Glioblastoma Patients.","phase":"NA","overall_status":"RECRUITING","enrollment_count":246,"lead_sponsor_name":"Jasper Gerritsen","has_results":false},{"nct_id":"NCT01177397","title":"Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":226,"lead_sponsor_name":"Celgene","has_results":true},{"nct_id":"NCT06273176","title":"The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma","phase":"","overall_status":"RECRUITING","enrollment_count":225,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT04116411","title":"A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":220,"lead_sponsor_name":"Cecilia Soderberg-Naucler","has_results":false},{"nct_id":"NCT01800695","title":"Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":202,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT03631823","title":"Gut Microbiota and Glioblastoma Multiforme Prognosis","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT06218524","title":"The Effectiveness of HP and TMZ Synergism on Adult Recurrence GBM","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Southern Medical University, China","has_results":false},{"nct_id":"NCT00083512","title":"Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04810182","title":"Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS","phase":"","overall_status":"COMPLETED","enrollment_count":192,"lead_sponsor_name":"Istituto Oncologico Veneto IRCCS","has_results":false},{"nct_id":"NCT06810544","title":"Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":191,"lead_sponsor_name":"Tango Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06466031","title":"Application of FET-PET in Fusion With MRI in the Treatment of Glioblastoma Multiforme [TYR-GLIO]","phase":"NA","overall_status":"RECRUITING","enrollment_count":189,"lead_sponsor_name":"Copernicus Memorial Hospital","has_results":false},{"nct_id":"NCT06630260","title":"5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":182,"lead_sponsor_name":"Institute of Cancer Research, United Kingdom","has_results":false},{"nct_id":"NCT06346821","title":"Tumor Treating Fields for Newly Diagnosed Glioblastoma: Two Emulated Trials With Chinese Multi-Hospital Based Real-World Data","phase":"","overall_status":"COMPLETED","enrollment_count":181,"lead_sponsor_name":"Sichuan University","has_results":false},{"nct_id":"NCT03423628","title":"A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02465268","title":"Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":175,"lead_sponsor_name":"University of Florida","has_results":true},{"nct_id":"NCT05708352","title":"A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":170,"lead_sponsor_name":"Cedars-Sinai Medical Center","has_results":false},{"nct_id":"NCT03607643","title":"A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":160,"lead_sponsor_name":"Leaf Vertical Inc.","has_results":false},{"nct_id":"NCT05086497","title":"WBSI Guided Personalized Delivery of TTFields","phase":"NA","overall_status":"RECRUITING","enrollment_count":155,"lead_sponsor_name":"Abramson Cancer Center at Penn Medicine","has_results":false},{"nct_id":"NCT05495295","title":"First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":149,"lead_sponsor_name":"Phost'In Therapeutics","has_results":false},{"nct_id":"NCT04188535","title":"Serial MRI Scans During Radiation Therapy","phase":"NA","overall_status":"RECRUITING","enrollment_count":149,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT04250922","title":"LAM561 With RT and TMZ for Adults With Glioblastoma","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":144,"lead_sponsor_name":"Laminar Pharmaceuticals","has_results":false},{"nct_id":"NCT06954636","title":"Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational Study","phase":"","overall_status":"RECRUITING","enrollment_count":128,"lead_sponsor_name":"Sied Kebir","has_results":false},{"nct_id":"NCT05671016","title":"Brain Imaging to Predict Toxicity in Elderly Patients After Radiotherapy","phase":"","overall_status":"COMPLETED","enrollment_count":125,"lead_sponsor_name":"Brighton and Sussex University Hospitals NHS Trust","has_results":false},{"nct_id":"NCT05917821","title":"New Antigens Against Glioblastoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT05843253","title":"Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Nationwide Children's Hospital","has_results":false},{"nct_id":"NCT02974738","title":"A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":false},{"nct_id":"NCT03225300","title":"Simultaneous Integrated Boost in Malignant Glioma Patients Treated With Chemoradiation","phase":"NA","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Taichung Veterans General Hospital","has_results":false},{"nct_id":"NCT00441142","title":"Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":119,"lead_sponsor_name":"Patrick Y. Wen, MD","has_results":true},{"nct_id":"NCT04277221","title":"ADCTA for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM)","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":118,"lead_sponsor_name":"Safe Save Medical Cell Sciences & Technology Co.,Ltd.","has_results":false},{"nct_id":"NCT02717962","title":"Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":118,"lead_sponsor_name":"Kintara Therapeutics, Inc.","has_results":false},{"nct_id":"NCT01353625","title":"Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":118,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT04726397","title":"UNIty-Based MR-Linac Guided AdapTive RadiothErapy for High GraDe Glioma: a Phase 2 Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":108,"lead_sponsor_name":"Sunnybrook Health Sciences Centre","has_results":false},{"nct_id":"NCT04195139","title":"Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":103,"lead_sponsor_name":"University of Sydney","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}